External broker reports(aggregated public sources), Axis Direct

Axis Direct

Axis Direct is the flagship brand under Axis Securities Limited, a subsidiary of Axis Bank in India. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only.  Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

External broker reports(aggregated public sources)

Axis Direct is the flagship brand under Axis Securities Limited, a subsidiary of Axis Bank in India. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

Equity Bottom-Up

<ul><li>AIL reported revenue growth of 7.0% YoY in Q4FY23 (vs. our expectations of 10.7% YoY), which stood below the IPM growth of 11.0% (IPM: Indian Pharma Industry, Source: AIOCD).</li><li>A product mix change, higher proportion towards Anti Diabetic segment, Mixtard and Novomix reported growth of 4.0% and -1.1% on YoY respctively led to lower topline growth.</li><li>Further, growth in other key therapies like Gasteroinsteinal (+11.4% YoY) and Hormones (+27.4% YoY) similar to IPM growth.</li></ul><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

AIL reported revenue growth of 7.0% YoY in Q4FY23 (vs. our expectations of 10.7% YoY), which stood below the IPM growth of 11.0% (IPM: Indian Pharma Industry, Source: AIOCD).A product mix change, higher proportion towards Anti Diabetic segment, Mixtard and Novomix reported growth of 4.0% and -1.1% on YoY respctively led to lower topline growth.Further, growth in other key therapies like Gasteroinsteinal (+11.4% YoY) and Hormones (+27.4% YoY) similar to IPM growth.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Abbott India Ltd - Missed on Topline Growth

ABB India Ltd

Abbott India Ltd - Missed on Topline Growth